{"news_desk": "Business", "print_page": null, "subsection_name": "DealBook", "section_name": "Business Day", "byline": {"original": "By ROBERT CYRAN", "person": [{"firstname": "Robert", "rank": 1, "lastname": "CYRAN", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "485", "keywords": [{"rank": "1", "value": "Valeant Pharmaceuticals International Inc", "is_major": "N", "name": "organizations"}, {"rank": "2", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}, {"rank": "3", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "name": "subject"}], "lead_paragraph": "The pharmaceutical aimed to grow through acquisitions and price increases, but ran into a wall of opposition. Now it and other drug makers are facing the industry\u2019s limitations.", "pub_date": "2017-01-10T20:11:51+0000", "document_type": "article", "source": "The New York Times", "snippet": "The pharmaceutical aimed to grow through acquisitions and price increases, but ran into a wall of opposition. Now it and other drug makers are facing the industry\u2019s limitations....", "multimedia": [], "web_url": "http://www.nytimes.com/2017/01/10/business/dealbook/how-valeant-had-a-bright-idea-but-took-it-too-far.html", "slideshow_credits": null, "blog": [], "_id": "5875400c95d0e03926079f8d", "headline": {"main": "How Valeant Had a Bright Idea but Took It Too Far", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}}